helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2025-18-2-153-159helmholtzeyeinstitute-1779Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWSИзбыточное рубцевание в хирургии глаукомы. Часть 3. Методы предоперационной профилактикиWound healing in glaucoma surgery. Part 3. Methods of preoperative preventionhttps://orcid.org/0000-0001-6922-0464ПетровС. Ю.PetrovS. Yu.

Петров Сергей Юрьевич — д-р мед. наук, начальник отдела глаукомы.

ул. Садовая-Черногрязская, д. 14/19, Москва, 105062

Sergey Yu. Petrov — Dr. of Med. Sci., head of glaucoma department.

14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062

glaucomatosis@gmail.comhttps://orcid.org/0000-0003-1527-9414ЯниЕ. В.YaniE. V.

Яни Елена Владимировна — канд. мед. наук, руководитель отдела инфекционных и аллергических заболеваний глаз.

ул. Садовая-Черногрязская, д. 14/19, Москва, 105062

Elena V. Yani — Cand. of Med. Sci., head of the department of infectious and allergic eye diseasest.

14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062

https://orcid.org/0000-0001-9082-4537ФилипповаО. М.FilippovaO. M.

Филиппова Ольга Маратовна — канд. мед. наук, научный сотрудник отдела глаукомы.

ул. Садовая-Черногрязская, д. 14/19, Москва, 105062

Olga M. Filippova — Cand. of Med. Sci., researcher, glaucoma department.

14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062

https://orcid.org/0009-0006-8100-9681ЕпхиеваА. Д.EpkhievaA. D.

Епхиева Анжела Давидовна — аспирант.

ул. Садовая-Черногрязская, д. 14/19, Москва, 105062

Anzhela D. Epkhieva — PhD student of glaucoma department.

14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062

ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава РоссииРоссияHelmholtz National Medical Research Center of Eye DiseasesRussian Federation202514062025182153159Copyright © Петров С.Ю., Яни Е.В., Филиппова О.М., Епхиева А.Д., 20252025Петров С.Ю., Яни Е.В., Филиппова О.М., Епхиева А.Д.Petrov S.Y., Yani E.V., Filippova O.M., Epkhieva A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/1779

Изучение факторов профилактики избыточного рубцевания при антиглаукомной хирургии создает фундамент для разработки методов воздействия на эти процессы в послеоперационном периоде с целью повышения эффективности вмешательства. Анализ литературы показал, что систематизированный подход к подготовке успешного оперативного лечения глаукомы должен включать рациональный выбор предшествующей гипотензивной терапии с бесконсервантными препаратами, профилактику повреждений глазной поверхности с применением слезозаместительной и иммуносупрессивной терапии, а также предоперационную противовоспалительную профилактику стероидными и нестероидными средствами с доказанной офтальмогипертензионной безопасностью.

Study of factors preventing excessive scarring in antiglaucoma surgery creates a foundation for developing methods of influencing these processes in the postoperative period in order to increase the effectiveness of the intervention. Analysis of the literature showed that a systematic approach to preparing for successful surgical treatment of glaucoma should include a rational choice of previous hypotensive therapy with preservative-free drugs, prevention of damage to the ocular surface using tear substitute and immunosuppressive therapy, as well as preoperative anti-inflammatory prophylaxis with steroid and non-steroid agents with proven ophthalmic hypertension safety.

глаукомахирургия глаукомыглазная поверхностьизбыточное рубцеваниеglaucomaglaucoma surgeryocular surfacewound healingReferencesMai DD, Ingram Z, Oberfeld B, Sola-Del Valle D. Combined microinvasive glaucoma surgery - A review of the literature and future directions. Semin Ophthalmol. 2023; 38 (6): 529–36. doi:10.1080/08820538.2023.2181665Mai DD, Ingram Z, Oberfeld B, Sola-Del Valle D. Combined microinvasive glaucoma surgery - A review of the literature and future directions. Semin Ophthalmol. 2023; 38 (6): 529–36. doi:10.1080/08820538.2023.2181665Meshksar A, Razeghinejhad MR, Azimi A. Ab-interno trabeculotomy procedures: A review. J Curr Ophthalmol. 2023; 35 (2): 110–24. doi:10.4103/joco.joco_45_23Meshksar A, Razeghinejhad MR, Azimi A. Ab-interno trabeculotomy procedures: A review. J Curr Ophthalmol. 2023; 35 (2): 110–24. doi:10.4103/joco.joco_45_23Traverso CE, Carassa RG, Fea AM, et al. Effectiveness and safety of xen gel stent in glaucoma surgery: A systematic review of the literature. J Clin Med. 2023; 12 (16). doi:10.3390/jcm12165339Traverso CE, Carassa RG, Fea AM, et al. Effectiveness and safety of xen gel stent in glaucoma surgery: A systematic review of the literature. J Clin Med. 2023; 12 (16). doi:10.3390/jcm12165339Измайлова Н.С., Петров С.Ю., Дзебисова А.Д. Избыточное рубцевание в хирургии глаукомы. Часть 1. Морфология рубцового процесса. Российский офтальмологический журнал. 2024; 17 (4): 116–20. https://doi.org/10.21516/2072-0076-2024-17-4-116-120Izmailova N.S., Petrov S.Yu., Dzebisova A.D. Wound healing in glaucoma surgery. Part 1. Wound healing morphology. Russian ophthalmological journal. 2024; 17 (4): 116–20 (In Russ.). https://doi.org/10.21516/2072-0076-2024-17-4-116-120Измайлова Н.С., Петров С.Ю., Епхиева А.Д. Избыточное рубцевание в хирургии глаукомы. Часть 2. Факторы риска. Российский офтальмологический журнал. 2025; 18 (1): 145–9. https://doi.org/10.21516/2072-0076-2025-18-1-145-149Izmailova N.S., Petrov S.Yu., Epkhieva A.D. Wound healing in glaucoma surgery. Part 2. Risk factors. Russian ophthalmological journal. 2025; 18 (1): 145–9 (In Russ.). https://doi.org/10.21516/2072-0076-2025-18-1-145-149Yu DY, Morgan WH, Sun X, et al. The critical role of the conjunctiva in glaucoma filtration surgery. Prog Retin Eye Res. 2009; 28 (5): 303–28. doi:10.1016/j.preteyeres.2009.06.004Yu DY, Morgan WH, Sun X, et al. The critical role of the conjunctiva in glaucoma filtration surgery. Prog Retin Eye Res. 2009; 28 (5): 303–28. doi:10.1016/j.preteyeres.2009.06.004The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5 (2): 75–92. doi:10.1016/s1542-0124(12)70081-2The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5 (2): 75–92. doi:10.1016/s1542-0124(12)70081-2Barabino S, Aragona P, di Zazzo A, Rolando M, with the contribution of selected ocular surface experts from the Societa Italiana di Dacriologia e Superficie O. Updated definition and classification of dry eye disease: Renewed proposals using the nominal group and Delphi techniques. Eur J Ophthalmol. 2021; 31 (1): 42–8. doi:10.1177/1120672120960586Barabino S, Aragona P, di Zazzo A, Rolando M, with the contribution of selected ocular surface experts from the Societa Italiana di Dacriologia e Superficie O. Updated definition and classification of dry eye disease: Renewed proposals using the nominal group and Delphi techniques. Eur J Ophthalmol. 2021; 31 (1): 42–8. doi:10.1177/1120672120960586Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002; 86 (4): 418–23. doi:10.1136/bjo.86.4.418Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002; 86 (4): 418–23. doi:10.1136/bjo.86.4.418Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010; 29 (6): 618–21. doi:10.1097/ICO.0b013e3181c325b2Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010; 29 (6): 618–21. doi:10.1097/ICO.0b013e3181c325b2Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008; 17 (5): 350–35. doi:10.1097/IJG.0b013e31815c5f4fLeung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008; 17 (5): 350–35. doi:10.1097/IJG.0b013e31815c5f4fRossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009; 19 (4): 572–9. doi:10.1177/112067210901900409Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009; 19 (4): 572–9. doi:10.1177/112067210901900409Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004; 111 (1): 45–52. doi:10.1016/j.ophtha.2003.03.001Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004; 111 (1): 45–52. doi:10.1016/j.ophtha.2003.03.001Arita R, Itoh K, Maeda S, et al. Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands. Cornea. 2012; 31 (11): 1229–34. doi:10.1097/ICO.0b013e31823f8e7dArita R, Itoh K, Maeda S, et al. Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands. Cornea. 2012; 31 (11): 1229–34. doi:10.1097/ICO.0b013e31823f8e7dPetounis AD, Akritopoulos P. Influence of topical and systemic beta-blockers on tear production. Int Ophthalmol. 1989; 13 (1–2): 75–80. doi:10.1007/BF02028642Petounis AD, Akritopoulos P. Influence of topical and systemic beta-blockers on tear production. Int Ophthalmol. 1989; 13 (1–2): 75–80. doi:10.1007/BF02028642Aydin Kurna S, Acikgoz S, Altun A, et al. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study. J Ophthalmol. 2014; 2014: 460483. doi:10.1155/2014/460483Aydin Kurna S, Acikgoz S, Altun A, et al. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study. J Ophthalmol. 2014; 2014: 460483. doi:10.1155/2014/460483Rabinowitz MP, Katz LJ, Moster M.R, et al. Unilateral prostaglandin-associated periorbitopathy: a syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid. Ophthalmic Plast Reconstr Surg. 2015; 31 (5): 373–8. doi:10.1097/IOP.0000000000000351Rabinowitz MP, Katz LJ, Moster M.R, et al. Unilateral prostaglandin-associated periorbitopathy: a syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid. Ophthalmic Plast Reconstr Surg. 2015; 31 (5): 373–8. doi:10.1097/IOP.0000000000000351Figus M, Nardi M, Piaggi P, et al. Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients. Eye (Lond). 2014; 28 (4): 422–9. doi:10.1038/eye.2013.304Figus M, Nardi M, Piaggi P, et al. Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients. Eye (Lond). 2014; 28 (4): 422–9. doi:10.1038/eye.2013.304Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23 (5): 490–6. doi:10.1097/01.ico.0000116526.57227.82Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23 (5): 490–6. doi:10.1097/01.ico.0000116526.57227.82Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997; 115 (7): 847–52. doi:10.1001/archopht.1997.01100160017002Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997; 115 (7): 847–52. doi:10.1001/archopht.1997.01100160017002Kamath AP, Satyanarayana S, Rodrigues F. Ocular surface changes in primary open angle glaucoma with long term topical anti glaucoma medication. Med J Armed Forces India. 2007; 63 (4): 341–5. doi:10.1016/S0377-1237(07)80011-6Kamath AP, Satyanarayana S, Rodrigues F. Ocular surface changes in primary open angle glaucoma with long term topical anti glaucoma medication. Med J Armed Forces India. 2007; 63 (4): 341–5. doi:10.1016/S0377-1237(07)80011-6Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002; 11 (2): 119–26. doi:10.1097/00061198-200204000-00007Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002; 11 (2): 119–26. doi:10.1097/00061198-200204000-00007Corrales RM, Stern ME, De Paiva CS, et al. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci. 2006; 47 (8): 3293–302. doi:10.1167/iovs.05-1382Corrales RM, Stern ME, De Paiva CS, et al. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci. 2006; 47 (8): 3293–302. doi:10.1167/iovs.05-1382Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994; 112 (11): 1437–45. doi:10.1001/archopht.1994.01090230051020Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994; 112 (11): 1437–45. doi:10.1001/archopht.1994.01090230051020Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999; 106 (3): 556–63. doi:10.1016/S0161-6420(99)90116-1Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999; 106 (3): 556–63. doi:10.1016/S0161-6420(99)90116-1Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018; 186: 116–27. doi:10.1016/j.ajo.2017.11.019Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018; 186: 116–27. doi:10.1016/j.ajo.2017.11.019Zaman F, Gieser SC, Schwartz GF, Swan C, Williams JM. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting. Curr Med Res Opin. 2021; 37 (6): 1011–20. doi:10.1080/03007995.2021.1901222Zaman F, Gieser SC, Schwartz GF, Swan C, Williams JM. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting. Curr Med Res Opin. 2021; 37 (6): 1011–20. doi:10.1080/03007995.2021.1901222Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene Bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: Pooled phase 3 study findings. J Glaucoma. 2018; 27 (1): 7–15. doi:10.1097/IJG.0000000000000831Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene Bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: Pooled phase 3 study findings. J Glaucoma. 2018; 27 (1): 7–15. doi:10.1097/IJG.0000000000000831Chen W, Zhang Z, Hu J, et al. Changes in rabbit corneal innervation induced by the topical application of benzalkonium chloride. Cornea. 2013; 32 (12): 1599–606. doi:10.1097/ICO.0b013e3182a8196fChen W, Zhang Z, Hu J, et al. Changes in rabbit corneal innervation induced by the topical application of benzalkonium chloride. Cornea. 2013; 32 (12): 1599–606. doi:10.1097/ICO.0b013e3182a8196fBaratz KH, Nau CB, Winter EJ, et al. Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study. Cornea. 2006; 25 (9): 1046–52. doi:10.1097/01.ico.0000230499.07273.c5Baratz KH, Nau CB, Winter EJ, et al. Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study. Cornea. 2006; 25 (9): 1046–52. doi:10.1097/01.ico.0000230499.07273.c5Lee SE, Lim HB, Oh S, Lee K, Lee SB. Effects of topical anti-glaucoma medications on outcomes of endoscopic dacryocystorhinostomy: Comparison with age- and sex-matched controls. J Clin Med. 2024; 13 (2). doi:10.3390/jcm13020634Lee SE, Lim HB, Oh S, Lee K, Lee SB. Effects of topical anti-glaucoma medications on outcomes of endoscopic dacryocystorhinostomy: Comparison with age- and sex-matched controls. J Clin Med. 2024; 13 (2). doi:10.3390/jcm13020634Stevens AM, Kestelyn PA, De Bacquer D, Kestelyn PG. Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial. Acta Ophthalmol. 2012; 90 (3): e221-224. doi:10.1111/j.1755-3768.2011.02338.xStevens AM, Kestelyn PA, De Bacquer D, Kestelyn PG. Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial. Acta Ophthalmol. 2012; 90 (3): e221-224. doi:10.1111/j.1755-3768.2011.02338.xSherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989; 96 (3): 327–35. doi:10.1016/s0161-6420(89)32888-0Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989; 96 (3): 327–35. doi:10.1016/s0161-6420(89)32888-0Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994; 101 (3): 454–60. doi:10.1016/s0161-6420(94)31322-4Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994; 101 (3): 454–60. doi:10.1016/s0161-6420(94)31322-4Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004; 45 (5): 1360–8. doi:10.1167/iovs.03-1067Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004; 45 (5): 1360–8. doi:10.1167/iovs.03-1067Pauly A, Meloni M, Brignole-Baudouin F, Warnet JM, Baudouin C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci. 2009; 50 (4): 1644–52. doi:10.1167/iovs.08-2992Pauly A, Meloni M, Brignole-Baudouin F, Warnet JM, Baudouin C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci. 2009; 50 (4): 1644–52. doi:10.1167/iovs.08-2992Lavin MJ, Wormald RP, Migdal CS, Hitchings R.A. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990; 108 (11): 1543–8. doi:10.1001/archopht.1990.01070130045027Lavin MJ, Wormald RP, Migdal CS, Hitchings R.A. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990; 108 (11): 1543–8. doi:10.1001/archopht.1990.01070130045027Tailor R, Batra R, Mohamed S. A National survey of glaucoma specialists on the preoperative (Trabeculectomy) management of the ocular surface. Semin Ophthalmol. 2016; 31 (6): 519–25. doi:10.3109/08820538.2014.986585Tailor R, Batra R, Mohamed S. A National survey of glaucoma specialists on the preoperative (Trabeculectomy) management of the ocular surface. Semin Ophthalmol. 2016; 31 (6): 519–25. doi:10.3109/08820538.2014.986585Lorenz K, Wasielica-Poslednik J, Bell K, et al. Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma. PLoS One. 2017; 12 (2): e0171636. doi:10.1371/journal.pone.0171636Lorenz K, Wasielica-Poslednik J, Bell K, et al. Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma. PLoS One. 2017; 12 (2): e0171636. doi:10.1371/journal.pone.0171636Bron A, Chiambaretta F, Pouliquen P, Rigal D, Rouland JF. [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension]. J Fr Ophtalmol. 2003; 26 (7): 668–74. 2003 Sep; 26 (7): 668–74. French. PMID: 13130253.Bron A, Chiambaretta F, Pouliquen P, Rigal D, Rouland JF. [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension]. J Fr Ophtalmol. 2003; 26 (7): 668–74. 2003 Sep; 26 (7): 668–74. French. PMID: 13130253.Campagna P, Macri A, Rolando M, Calabria G. Chronic topical eye preservativefree beta-blocker therapy effect on the ocular surface in glaucomatous patients. Acta Ophthalmol Scand Suppl. 1997; 224: 53. doi:10.1111/j.1600-0420.1997.tb00480.xCampagna P, Macri A, Rolando M, Calabria G. Chronic topical eye preservativefree beta-blocker therapy effect on the ocular surface in glaucomatous patients. Acta Ophthalmol Scand Suppl. 1997; 224: 53. doi:10.1111/j.1600-0420.1997.tb00480.xUusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010; 88 (3): 329–36. doi:10.1111/j.1755-3768.2010.01907.xUusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010; 88 (3): 329–36. doi:10.1111/j.1755-3768.2010.01907.xКаменских Т.Г., Веселова Е.В., Колбенев И.О., Петрова Ю.В. Влияние различных консервантов на состояние роговицы при инстилляции аналогов простагландинов. Национальный журнал Глаукома. 2015; 14 (3): 49–57.Kamenskikh T.G., Veselova E.V., Kolbenev I.O., Petrova Y.V. Effect of different preservatives on the cornea during instillation of prostaglandin analogues. Russian journal of Glaucoma. 2015; 14 (3): 49–57 (In Russ.).Gandolfi S, Paredes T, Goldberg I, et al. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol. 2012; 22 (1): 34–44. doi:10.5301/ejo.5000001Gandolfi S, Paredes T, Goldberg I, et al. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol. 2012; 22 (1): 34–44. doi:10.5301/ejo.5000001Gimenez-Gomez R, Garcia-Catalan MR, Gallardo-Galera JM. Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins. Arch Soc Esp Oftalmol. 2013; 88 (3): 88–91. doi:10.1016/j.oftal.2012.06.003Gimenez-Gomez R, Garcia-Catalan MR, Gallardo-Galera JM. Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins. Arch Soc Esp Oftalmol. 2013; 88 (3): 88–91. doi:10.1016/j.oftal.2012.06.003Armaly M.F. Effect of corticosteroids on intraocular pressure and fluid dynamics. Ii. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol. 1963; 70: 492–9. doi:10.1001/archopht.1963.00960050494011Armaly M.F. Effect of corticosteroids on intraocular pressure and fluid dynamics. Ii. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol. 1963; 70: 492–9. doi:10.1001/archopht.1963.00960050494011Roberti G, Oddone F, Agnifili L, et al. Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020; 65 (4): 458–72. doi:10.1016/j.survophthal.2020.01.002Roberti G, Oddone F, Agnifili L, et al. Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020; 65 (4): 458–72. doi:10.1016/j.survophthal.2020.01.002Lewis JM, Priddy T, Judd J, et al. Intraocular pressure response to topical dexamethasone as a predictor for the development of primary open-angle glaucoma. Am J Ophthalmol. 1988; 106 (5): 607–12. doi:10.1016/0002-9394(88)90595-8Lewis JM, Priddy T, Judd J, et al. Intraocular pressure response to topical dexamethasone as a predictor for the development of primary open-angle glaucoma. Am J Ophthalmol. 1988; 106 (5): 607–12. doi:10.1016/0002-9394(88)90595-8Cantrill HL, Palmberg PF, Zink HA, et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975; 79 (6): 1012–7. doi:10.1016/0002-9394(75)90687-xCantrill HL, Palmberg PF, Zink HA, et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975; 79 (6): 1012–7. doi:10.1016/0002-9394(75)90687-xMindel JS, Tavitian HO, Smith H, Jr, Walker EC. Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol. 1980; 98 (9): 1577–8. doi:10.1001/archopht.1980.01020040429006Mindel JS, Tavitian HO, Smith H, Jr, Walker EC. Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol. 1980; 98 (9): 1577–8. doi:10.1001/archopht.1980.01020040429006Broadway DC, Grierson I, Sturmer J, Hitchings RA. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol. 1996; 114 (3): 262–7. doi:10.1001/archopht.1996.01100130258004Broadway DC, Grierson I, Sturmer J, Hitchings RA. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol. 1996; 114 (3): 262–7. doi:10.1001/archopht.1996.01100130258004Baudouin C, Nordmann JP, Denis P, et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefes Arch Clin Exp Ophthalmol. 2002; 240 (11): 929–35. doi:10.1007/s00417-002-0581-9Baudouin C, Nordmann JP, Denis P, et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefes Arch Clin Exp Ophthalmol. 2002; 240 (11): 929–35. doi:10.1007/s00417-002-0581-9Nguyen KD, Lee DA. Effect of steroids and nonsteroidal anti-inflammatory agents on human ocular fibroblast. Invest Ophthalmol Vis Sci. 1992 Aug; 33 (9): 2693–701. PMID: 1386351.Nguyen KD, Lee DA. Effect of steroids and nonsteroidal anti-inflammatory agents on human ocular fibroblast. Invest Ophthalmol Vis Sci. 1992 Aug; 33 (9): 2693–701. PMID: 1386351.Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010; 117 (7): 1324–30. doi:10.1016/j.ophtha.2009.11.038Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010; 117 (7): 1324–30. doi:10.1016/j.ophtha.2009.11.038Iyer JV, Zhao Y, Lim FPM, Tong L, Wong TTL. Ocular lubricant use in medically and surgically treated glaucoma: a retrospective longitudinal analysis. Clin Ophthalmol. 2017; 11: 1191–6. doi:10.2147/OPTH.S134570Iyer JV, Zhao Y, Lim FPM, Tong L, Wong TTL. Ocular lubricant use in medically and surgically treated glaucoma: a retrospective longitudinal analysis. Clin Ophthalmol. 2017; 11: 1191–6. doi:10.2147/OPTH.S134570Prabhasawat P, Ruangvaravate N, Tesavibul N, Thewthong M. Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran versus 0.18% Sodium Hyaluronate in the treatment of ocular surface disease in glaucoma patients: A randomized, double-blind, and controlled study. J Ocul Pharmacol Ther. 2015; 31 (6): 323–9. doi:10.1089/jop.2014.0115Prabhasawat P, Ruangvaravate N, Tesavibul N, Thewthong M. Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran versus 0.18% Sodium Hyaluronate in the treatment of ocular surface disease in glaucoma patients: A randomized, double-blind, and controlled study. J Ocul Pharmacol Ther. 2015; 31 (6): 323–9. doi:10.1089/jop.2014.0115Pauloin T, Dutot M, Warnet JM, Rat P. In vitro modulation of preservative toxicity: high molecular weight hyaluronan decreases apoptosis and oxidative stress induced by benzalkonium chloride. Eur J Pharm Sci. 2008; 34 (4–5): 263–73. doi:10.1016/j.ejps.2008.04.006Pauloin T, Dutot M, Warnet JM, Rat P. In vitro modulation of preservative toxicity: high molecular weight hyaluronan decreases apoptosis and oxidative stress induced by benzalkonium chloride. Eur J Pharm Sci. 2008; 34 (4–5): 263–73. doi:10.1016/j.ejps.2008.04.006Alpar JJ. Sodium hyaluronate (Healon) in glaucoma filtering procedures. Ophthalmic Surg. 1986 Nov; 17 (11): 724–30. PMID: 3808582.Alpar JJ. Sodium hyaluronate (Healon) in glaucoma filtering procedures. Ophthalmic Surg. 1986 Nov; 17 (11): 724–30. PMID: 3808582.Sherwin JC, Ratnarajan G, Elahi B, Bilkiewicz-Pawelec A, Salmon JF. Effect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial. Clin Exp Ophthalmol. 2018; 46 (8): 888–94. doi:10.1111/ceo.13311Sherwin JC, Ratnarajan G, Elahi B, Bilkiewicz-Pawelec A, Salmon JF. Effect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial. Clin Exp Ophthalmol. 2018; 46 (8): 888–94. doi:10.1111/ceo.13311Arita R, Morishige N, Shirakawa R, Sato Y, Amano S. Effects of eyelid warming devices on tear film parameters in normal subjects and patients with meibomian gland dysfunction. Ocul Surf. 2015; 13 (4): 321–30. doi:10.1016/j.jtos.2015.04.005Arita R, Morishige N, Shirakawa R, Sato Y, Amano S. Effects of eyelid warming devices on tear film parameters in normal subjects and patients with meibomian gland dysfunction. Ocul Surf. 2015; 13 (4): 321–30. doi:10.1016/j.jtos.2015.04.005Saini M, Dhiman R, Dada T, Tandon R, Vanathi M. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye (Lond). 2015; 29 (6): 808–14. doi:10.1038/eye.2015.40Saini M, Dhiman R, Dada T, Tandon R, Vanathi M. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye (Lond). 2015; 29 (6): 808–14. doi:10.1038/eye.2015.40Perez VL, Pflugfelder SC, Zhang S, et al. Novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016; 14 (2): 207–15. doi:10.1016/j.jtos.2016.01.001Perez VL, Pflugfelder SC, Zhang S, et al. Novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016; 14 (2): 207–15. doi:10.1016/j.jtos.2016.01.001Deinema LA, Vingrys AJ, Wong CY, et al. A randomized, double-masked, placebo-controlled clinical trial of two forms of Omega-3 supplements for treating dry eye disease. Ophthalmology. 2017; 124 (1): 43–52. doi:10.1016/j.ophtha.2016.09.023Deinema LA, Vingrys AJ, Wong CY, et al. A randomized, double-masked, placebo-controlled clinical trial of two forms of Omega-3 supplements for treating dry eye disease. Ophthalmology. 2017; 124 (1): 43–52. doi:10.1016/j.ophtha.2016.09.023Tellez-Vazquez J. Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study. Clin Ophthalmol. 2016; 10: 617–26. doi:10.2147/OPTH.S96433Tellez-Vazquez J. Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study. Clin Ophthalmol. 2016; 10: 617–26. doi:10.2147/OPTH.S96433Dry Eye A., Management Study Research G, Asbell PA, Maguire MG, Pistilli M, et al. n-3 Fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018; 378 (18): 1681–90. doi:10.1056/NEJMoa1709691Dry Eye A., Management Study Research G, Asbell PA, Maguire MG, Pistilli M, et al. n-3 Fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018; 378 (18): 1681–90. doi:10.1056/NEJMoa1709691Giannaccare G, Pellegrini M, Sebastiani S, et al. Efficacy of Omega-3 fatty acid supplementation for treatment of dry eye disease: A meta-analysis of randomized clinical trials. Cornea. 019; 38 (5): 565–73. doi:10.1097/ICO.0000000000001884Giannaccare G, Pellegrini M, Sebastiani S, et al. Efficacy of Omega-3 fatty acid supplementation for treatment of dry eye disease: A meta-analysis of randomized clinical trials. Cornea. 019; 38 (5): 565–73. doi:10.1097/ICO.0000000000001884Hussain M, Shtein RM, Pistilli M, et al. The Dry Eye Assessment and Management (DREAM) extension study — A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease. Ocul Surf. 2020; 18 (1): 47–55. doi:10.1016/j.jtos.2019.08.002Hussain M, Shtein RM, Pistilli M, et al. The Dry Eye Assessment and Management (DREAM) extension study — A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease. Ocul Surf. 2020; 18 (1): 47–55. doi:10.1016/j.jtos.2019.08.002

The authors declare that there are no conflicts of interest present.